ClinicalTrials.gg

Program

BR1015

A development code. Also written as “BR1015-A”.

Its studies are mostly in Essential Hypertension · Hypertension, led by Boryung Pharmaceutical.

Furthest: phase 1, since Aug 16, 202310 company-led studies, 4 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Boryung Pharmaceutical104 open or runningphase 1since Aug 16, 2023Aug 16, 2023none ahead

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 16, 2023First studies: 2 phase 1 studies in HypertensionFirst studyNCT06008028, NCT06008015
  2. Dec 17, 20244 phase 1 studies in Essential HypertensionNCT06744439, NCT06744426, NCT06744127 and 1 more
  3. Feb 12, 20264 phase 1 studies in Essential HypertensionNCT07421414, NCT07421401, NCT07421388 and 1 more

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 10 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07421414Essential Hypertension1Not yet recruitingJun 17, 202648
NCT07421401Essential Hypertension1Not yet recruitingJun 11, 202658
NCT07421388Essential Hypertension1Not yet recruitingJun 7, 202648
NCT07421375Essential Hypertension1Not yet recruitingMay 31, 202658
NCT06744439Essential Hypertension · Korea, Republic of1CompletedMar 16, 202549
NCT06744426Essential Hypertension · Korea, Republic of1CompletedMar 12, 202560
NCT06744127Essential Hypertension · Korea, Republic of1CompletedMar 14, 202558
NCT06744062Essential Hypertension · Korea, Republic of1CompletedMar 19, 202548
NCT06008028Hypertension · Korea, Republic of1CompletedOct 6, 202357
NCT06008015Hypertension · Korea, Republic of1CompletedOct 3, 202344

How it is read

Names in the registry

  • “BR1015”, 6 entries
  • “BR1015-A”, 4 entries

Codes read as this program: BR1015.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.